| abstract |
An example of the combination drug of the present invention, which is to be used for treating caner in a target, comprises (a1) an immune responsive cell expressing a cell-surface molecule specifically recognizing a cancer antigen, interleukin 7 and CCL19, or (a2) one or more kinds of cells or nucleic acid delivery vehicles cooperatively containing a nucleic acid encoding interleukin 7 and a nucleic acid encoding CCL19, or a combination thereof, and (b) an immunosuppression inhibitor. An example of the immune responsive cell expresses a cell-surface molecule specifically recognizing a cancer antigen, interleukin 7, CCL19 and an immunosuppression inhibitory polypeptide. |